⚛️量子位•Freshcollected in 67m
Molecular Heart secures over $100M for AI protein research
💡Major $100M+ funding for AI protein research—a key player in the biotech AI revolution.
⚡ 30-Second TL;DR
What Changed
Secured over $100 million in new funding
Why It Matters
This significant capital injection signals a maturing market for AI-driven drug discovery and biological engineering, accelerating the development of new therapeutics.
What To Do Next
Follow Molecular Heart's research publications to understand how their new infrastructure can be applied to your biotech or drug discovery projects.
Who should care:Founders & Product Leaders
🧠 Deep Insight
Web-grounded analysis with 11 cited sources.
🔑 Enhanced Key Takeaways
- •Molecular Heart (MoleculeMind) was founded in January 2022 by Xu Jinbo, who is recognized for pioneering AI protein structure prediction with his RaptorX method in 2016, a breakthrough that influenced DeepMind's AlphaFold.
- •The company has developed a proprietary AI protein generation model called NewOrigin, which boasts tens of billions of parameters and integrates sequence, structure, function, and evolution to customize functional proteins for various industrial applications.
- •Molecular Heart (MoleculeMind) has secured multiple funding rounds, including an angel round in April 2022, a strategic investment of over CNY 100 million in February 2023, and a Series A of hundreds of millions of yuan in September 2024, indicating substantial investor confidence in its AI protein design platform, MoleculeOS.
- •The company aims to apply its AI macromolecule optimization and design platform not only to large molecule drug design and enzyme optimization but also to broader fields such as synthetic biology, energy, materials, agriculture, industry, food, and consumer products.
📊 Competitor Analysis▸ Show
| Company | Category/Approach | Key Models/Platform | Latest Funding / Total | Key Results/Focus |
|---|---|---|---|---|
| Molecular Heart | AI Protein Design Platform, Foundation Models | MoleculeOS, NewOrigin (tens of billions of parameters) | Hundreds of millions of yuan (Series A, Sep 2024) | AI protein prediction, optimization, and design; custom functional proteins for drugs, enzymes, synthetic biology. |
| EvolutionaryScale | Foundation Models | ESM-3 / ESM-4 (15B params) | $682M+ ($540M Series A Jul 2025) | Foundation-model leader; generated functional GFP with no natural homologs. |
| Generate:Biomedicines | Vertically Integrated, Generative Therapeutics | Chroma diffusion model | $700M+ | Best-funded generative-therapeutics platform with active clinical pipeline. |
| Absci | Vertically Integrated, Generative Antibody Design | Proprietary AI models | NASDAQ: ABSI, $500M+ | Leader in generative-AI antibody design with wet-lab-validated de novo antibodies; first internal antibody (ABS-101) in Phase I. |
| Insilico Medicine | Vertically Integrated, Drug Discovery | Proprietary AI models | N/A | Farthest-along AI-designed drug (INS018_055 in Phase 2). |
| DeepMind Technologies | AI Research, Protein Structure Prediction | AlphaFold, AlphaProteo | N/A | Revolutionized protein structure prediction; AlphaProteo for protein design. |
🛠️ Technical Deep Dive
- Pioneering AI Method: Xu Jinbo's initial breakthrough, RaptorX, utilized deep residual convolutional neural networks to significantly improve protein structure prediction by modeling interactions between atoms.
- Foundation for AlphaFold: The deep learning method for protein contact/distance prediction, RaptorX-Contact, developed by Xu Jinbo, was widely adopted and laid the groundwork for DeepMind's AlphaFold.
- Core Platform (MoleculeOS): Molecular Heart's primary platform, MoleculeOS, employs a data-driven deep learning approach for comprehensive protein prediction, optimization, and design.
- Generative AI Model (NewOrigin): The company's advanced NewOrigin model is an industry-level AI protein generation model with tens of billions of parameters, uniquely integrating sequence, structure, function, and evolution to enable the rapid customization of functional proteins.
- Efficiency: The platform is designed to help biotechnologists quickly identify and generate suitable proteins, and to rapidly scale laboratory research results to industrial applications, capable of designing custom proteins in minutes.
🔮 Future ImplicationsAI analysis grounded in cited sources
Molecular Heart (MoleculeMind) will significantly accelerate the development of novel biologics and industrial enzymes.
Its advanced AI protein generation model, NewOrigin, with tens of billions of parameters, can customize functional proteins rapidly, reducing traditional R&D timelines and costs.
The company's expansion into diverse sectors like energy and agriculture will drive a broader adoption of AI in non-pharmaceutical biotechnology.
By applying its AI macromolecule optimization platform beyond drug design, Molecular Heart (MoleculeMind) demonstrates the versatility and potential of AI protein research to revolutionize multiple industries.
⏳ Timeline
2016-07
Xu Jinbo developed RaptorX, the first-generation AI method using deep residual convolutional neural networks for protein structure prediction, influencing DeepMind's AlphaFold.
2021-09
Xu Jinbo returned to China to establish his business.
2022-01
Molecular Heart (MoleculeMind) was established by Xu Jinbo.
2022-04
Molecular Heart (MoleculeMind) completed an angel round of financing.
2023-02
Molecular Heart (MoleculeMind) secured over CNY 100 million in strategic funding.
2024-09
Molecular Heart (MoleculeMind) completed hundreds of millions of yuan in Series A financing.
📎 Sources (11)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 量子位 ↗